LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fosphenytoin Sodium Injection, 100 mg, 2 mL and 500 mg, 10 mL vials, USP, the generic equivalent of Pfizer’s Cerebyx®. According to IMS, sales in 2006 of fosphenytoin sodium injection in the United States exceeded $73 million. The company expects to commence marketing of fosphenytoin sodium injection in August 2007. The product is AP rated, preservative-free and latex-free.
